SARMs在肌少症治疗中的机制与进展  

Therapeutic prospects of SARMs in sarcopenia

作　　者：袁瑾 方玲娜[2] 李翀[2] YUAN Jin;FANG Lingna;LI Chong(Jiangsu University,Zhenjiang 212000,China;Kunshan Hospital Affiliated of Jiangsu University,Suzhou 215300,China)

机构地区：[1]江苏省江苏大学,江苏镇江212000 [2]江苏大学附属昆山医院,江苏苏州215300

出　　处：《中国骨质疏松杂志》2024年第5期775-780,共6页Chinese Journal of Osteoporosis

基　　金：昆山市骨质疏松性骨质防治重点实验室(KZ2023005);2021年江苏省卫生健康委员会医学科研项目(Z2021026);2021年昆山市科技专项项目(KSZ2155)。

摘　　要：肌少症(sarcopenia)是当前一类严重影响老年人的日常行为能力和生活质量的疾病。因其发病率逐年增多,近些年各专家对于肌少症的研究也逐步深入。肌少症的治疗方法和治疗药物的研究备受关注,其中,选择性雄激素受体调节剂(selective androgen receptor modulators,SARMs)是一大研究热点,本篇综述的主要目的是探讨SARMs在肌少症的发生发展中的作用机制、研究和临床进展,以便于未来能更快更好地应用于临床治疗。Sarcopenia is a current group of diseases that seriously affect the daily behavior ability and quality of life of the elderly.Because its incidence has increased year by year,the research of various experts on sarcopenia has gradually deepened in recent years.The research on the treatment method and therapeutic drugs of sarcopenia has attracted much attention,among which Selective Androgen Receptor Modulators(SARMs)is a major research hotspot,the main purpose of this review is to explore the mechanism of action of SARMs in the occurrence and development of sarcopenia,research and clinical progress,so that it can be applied to clinical treatment faster and better in the future.

关 键 词：肌少症 选择性雄激素受体调节剂 雄激素 雄激素受体 

分 类 号：R589[医药卫生—内分泌] R685[医药卫生—内科学]